KR950031041A - 리포좀 용액 - Google Patents

리포좀 용액 Download PDF

Info

Publication number
KR950031041A
KR950031041A KR1019950001129A KR19950001129A KR950031041A KR 950031041 A KR950031041 A KR 950031041A KR 1019950001129 A KR1019950001129 A KR 1019950001129A KR 19950001129 A KR19950001129 A KR 19950001129A KR 950031041 A KR950031041 A KR 950031041A
Authority
KR
South Korea
Prior art keywords
lower alkyl
liposome solution
liposome
cor
aryl
Prior art date
Application number
KR1019950001129A
Other languages
English (en)
Inventor
훼르네 미셸
스테펜 한스
슈퍼삭소 안드레아스
트하일 프랭크-페터
Original Assignee
프리돌린 클라우스너·롤란드 보러
에프. 호프만-라 롯슈 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너·롤란드 보러, 에프. 호프만-라 롯슈 아크티엔 게젤샤프트 filed Critical 프리돌린 클라우스너·롤란드 보러
Publication of KR950031041A publication Critical patent/KR950031041A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

본 발명은 β-락타마아제 억제제 및 필요하다면 β-락탐 항생제를 함유하는 리포좀 수용액에 관한 것이다.

Description

리포좀 용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. β-락타마아제 억제제와 필요하다면 안정화제를 함유하는 리포좀 수용액.
  2. 제1항에 있어서, 상기 β-락타마아제 억제제가 타조박탐, 설박탐 또는 클라불란산이거나, 또는 유럽 특허 공보 A-0 508 234 호에 기재된 β-락타마아제 억제제이거나; 또는 하기 일반식 Ⅰ의 화합물 또는 약학적으로 양립가능한 이들의 염인 리포좀 용액.
    (상기식에서 R1및 R2중 하나는 -COR4, -CN, -CH2OR5또는 -SO2R6를 나타내고 나머지는 H, -COR4, -CN, -CH2OR5또는 -SO2R6또는 저급 알킬을 나타내고; R3는 H, 저급 알킬, 아릴-알킬, 아릴 또는 생체내에서 분해가능한 잔기; R4는 H, 저급 알킬, 저급 알콕시, 벤질옥시, 아미노 또는 저급 알킬아미노; R5는 H 또는 -CONH2: R6는 저급 알킬 및 n=0, 1 또는 2이다.)
  3. 제1항에 있어서, 포스파티딜콜린, 포스파티딜글리세롤 및 콜레스테롤의 몰비가 10 : 0내지 1 : 0내지 5인리포좀 용액.
  4. 제1내지 3항중 어느 한 항에 있어서, 상기 리포좀이 50내지 250㎚의 평균 직경을 갖는 리포좀 용액.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950001129A 1994-01-25 1995-01-24 리포좀 용액 KR950031041A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH213/94 1994-01-25
CH21394 1994-01-25

Publications (1)

Publication Number Publication Date
KR950031041A true KR950031041A (ko) 1995-12-18

Family

ID=4181848

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950001129A KR950031041A (ko) 1994-01-25 1995-01-24 리포좀 용액

Country Status (10)

Country Link
EP (1) EP0664117A1 (ko)
JP (1) JPH07206713A (ko)
KR (1) KR950031041A (ko)
CN (1) CN1111125A (ko)
AU (1) AU699142B2 (ko)
BR (1) BR9500296A (ko)
CA (1) CA2140701A1 (ko)
NZ (1) NZ270362A (ko)
RU (1) RU95101041A (ko)
ZA (1) ZA95404B (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
CN102048740B (zh) * 2010-12-02 2012-06-13 郝志艳 头孢曲松钠他唑巴坦钠药物组合物脂质体注射剂
CN103945842A (zh) 2011-09-09 2014-07-23 丘比斯特药物股份有限公司 治疗肺内感染的方法
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
CN102973568B (zh) * 2012-12-10 2014-08-27 江苏开元医药化工有限公司 头孢曲松钠舒巴坦钠的药物组合物脂质体的制备方法
EP3100732A1 (en) 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
CN112791074B (zh) * 2021-03-17 2022-10-04 中山大学 鱼腥草素和/或新鱼腥草素钠在制备ndm-1抑制剂中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
EP0479582A1 (en) * 1990-10-03 1992-04-08 Alexander Karl Friedrich Wilhelm Overweg Restorative periodontal technique

Also Published As

Publication number Publication date
CN1111125A (zh) 1995-11-08
RU95101041A (ru) 1997-02-27
CA2140701A1 (en) 1995-07-26
JPH07206713A (ja) 1995-08-08
AU1029895A (en) 1995-08-03
AU699142B2 (en) 1998-11-26
NZ270362A (en) 1996-10-28
BR9500296A (pt) 1995-10-17
EP0664117A1 (de) 1995-07-26
ZA95404B (en) 1995-07-25

Similar Documents

Publication Publication Date Title
KR950031041A (ko) 리포좀 용액
FI963169A0 (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
IE862297L (en) Sulfamic acid derivatives.
EP1815860A3 (en) Phosphate transport inhibitors
EP0992501A3 (en) Pyridonecarboxylic acid derivatives as antibacterial agents
KR940021059A (ko) 지질 대사 개선제
KR900011754A (ko) (디-3급-부틸히드록시페닐)티오 유도체
HUP0203117A2 (hu) Semleges kationos lipid nukleinsav és hatóanyag szállítására
HUP0004731A2 (hu) 2-Aril-benzo[b]tiofének alkalmazása ösztrogén elvonási szindróma kezelésére alkalmas gyógyszerkészítmények előállítására
AU2347088A (en) Polyamine derivatives as antineoplastic agents
ATE81655T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
KR890009962A (ko) 매뉴마이신 유도체, 이의 제조방법 및 용도
AU579872B2 (en) 2-amino-4-substituted oxazolines
NZ505614A (en) Pentasaccharides and pharmaceutical compositions thereof, useful as anti blood clotting agnets
ES8800236A1 (es) Un procedimiento para obtener acido-7-amino-3-propenilcefalosporanico y sus esteres.
ES8801922A1 (es) Procedimiento para la fabricacion de un ester acido 1 beta-(2-(2-amino-4-tiazolil)alquenoilamino)-3-cefem-4-carboxilico.
CA2127067A1 (fr) Derives d'acide phosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU6164096A (en) Urokinase receptor ligands
KR960031463A (ko) 효소 억제제의 존재하에서의 β-락탐 항생제의 효소적 합성방법
ATE41145T1 (de) Antikonvulsiermittel.
EA200200241A1 (ru) Новые производные изоиндолоиндолона, способ их получения и содержащие их фармацевтические композиции
WO1999005148A8 (en) Phosphonated agents and their antiangiogenic and antitumorigenic use
ATE267831T1 (de) Kristalle von cephemderivaten und verfahren zu ihrer herstellung
KR890000497A (ko) 아실 유도체
KR850002258A (ko) 디아진-에테닐 페닐옥삼산의 제조방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid